Wenxue Sun

Dr. Wenxue Sun


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in Environmental Pollution
Verified
Journal Article
Closed access
SZShiyuan Zhao
Shiyuan Zhao
HZHaitao Zhong
Haitao Zhong
CGChunmei Geng
Chunmei Geng
HXHongjia Xue
Hongjia Xue
CWChangshui Wang
Changshui Wang
PJPei Jiang
Pei Jiang

28 July 2025 in Annals of Medicine
Verified
Journal Article
Open access
MLMengmeng Liu
Mengmeng Liu
HWHongli Wang
Hongli Wang
YYYizhuang Yang
Yizhuang Yang
JWJianhua Wang
Jianhua Wang
ZSZhen Sun
Zhen Sun
LFLei Feng
Lei Feng
Background: Central nervous system (CNS) diseases pose significant therapeutic challenges owing to their complex pathophysiology and the restrictive nature of the blood-brain barrier (BBB). Introduction: Plant-derived exosome-like nanoparticles (PDELNs) exhibit intrinsic bioactivity, low immunogenicity, and ability to cross the BBB, making them a promising therapeutic strategy for CNS disorders. Discussion: This review explores the preparation, isolation, and characterization of PDELNs, with a focus on their therapeutic applications in CNS diseases. We also discuss different administration routes and the impact of functional modifications on BBB penetration. Conclusions: PDELNs offer scalability, biocompatibility, and natural pharmacological activity, which make them attractive candidates for CNS drug delivery. However, challenges remain, including standardized isolation, elucidation of BBB penetration mechanisms, and long-term stability and safety. Future research should focus on clarifying their mechanisms of action, optimizing preparation methods, and validating their long-term safety to facilitate the clinical translation of PDELNs. KEY MESSAGESPDELNs are derived from abundant plant sources, exhibit favorable physicochemical properties.PDELNs offer new possibilities for CNS therapies owing to their low immunogenicity, high biocompatibility, and ability to cross the BBB.

16 September 2021 in Journal of Chemistry
Verified
Journal Article
Open access
PDF file
FLFen Liu
Fen Liu
LLLuning Li
Luning Li
XTXinchen Tian
Xinchen Tian
DZDengtian Zhang
Dengtian Zhang
WSWenxue Sun
Wenxue Sun
SJShulong Jiang
Shulong Jiang
Rhizoma Paridis, the rhizome of liliaceous plants Paris polyphylla, is one of the most commonly used herbal drugs in China. Phytochemical and pharmacological studies have shown that steroid saponins were the major effective ingredients of Rhizoma Paridis to exert antitumor, anti-inflammatory, hemostasis, and antifibrosis functions. In this review, we discussed the chemical structures of steroid saponins and their related biological activity and mechanisms in cellular and animal models, aiming to provide a reference for future comprehensive exploitation and development of saponins.

18 January 2022 in Journal of Chemistry
Verified
Journal Article
Open access
PDF file
LLLuning Li
Luning Li
CZCunxin Zhang
Cunxin Zhang
CHChen Huang
Chen Huang
XTXinchen Tian
Xinchen Tian
WSWenxue Sun
Wenxue Sun
SJShulong Jiang
Shulong Jiang
Evodiamine is a natural alkaloid extracted from Fructus Evodia. This bioactive alkaloid has been reported to have a wide range of biological activities, including anti-injury, antiobesity, vasodilator, and anti-inflammatory effects. In recent years, it has been found that evodiamine has tumor-suppressive effects on a variety of tumors. There is growing evidence that evodiamine can inhibit the rapid proliferation of tumor cells, induce cell cycle arrest at a certain phase, increase the incidence of apoptosis, promote autophagy, inhibit microangiogenesis and migration, and regulate immunotherapy. Evodiamine can inhibit Wnt/β-catenin, mTOR, NF-κB, PI3K/AKT, JAK-STAT, and other signaling pathways in various cancer cells, and it can significantly downregulate the expression of many tumor markers, such as VEGF and COX-2. These facts partially explain the antitumor mechanism of evodiamine. In this article, the antitumor mechanism of evodiamine was reviewed to provide the basis for its clinical application and therapeutic development in the future.

23 February 2024 in Pharmaceutical Biology
Verified
Journal Article
Open access
YGYujin Guo
Yujin Guo
BCBeibei Chen
Beibei Chen
JGJinxiu Guo
Jinxiu Guo
PJPei Jiang
Pei Jiang
JWJianhua Wang
Jianhua Wang
WSWenxue Sun
Wenxue Sun
ContextPodophyllotoxin (PPT) derivatives, used in cancer therapy, require development toward enhanced efficacy and reduced toxicity.ObjectiveThis study synthesizes PPT derivatives to assess their anticancer activities.Materials and methodsCompounds E1-E16 antiproliferative activity was tested against four human cancer cell lines (H446, MCF-7, HeLa, A549) and two normal cell lines (L02, BEAS-2B) using the CCK-8 assay. The effects of compound E5 on A549 cell growth were evaluated through molecular docking, in vitro assays (flow cytometry, wound healing, Transwell, colony formation, Western blot), and in vivo tests in female BALB/c nude mice treated with E5 (2 and 4 mg/kg). E5 (4 mg/kg) significantly reduced xenograft tumor growth compared to the DMSO control group.ResultsAmong the 16 PPT derivatives tested for cytotoxicity, E5 exhibited potent effects against A549 cells (IC50: 0.35 +/- 0.13 mu M) and exceeded the reference drugs PPT and etoposide to inhibit the growth of xenograft tumours. E5-induced cell cycle arrest in the S and G2/M phases accelerated tubulin depolymerization and triggered apoptosis and mitochondrial depolarization while regulating the expression of apoptosis-related proteins and effectively inhibited cell migration and invasion, suggesting a potential to limit metastasis. Molecular docking showed binding of E5 to tubulin at the colchicine site and to Akt, with a consequent down-regulation of PI3K/Akt pathway proteins.Discussion and conclusionsThis research lays the groundwork for advancing cancer treatment through developing and using PPT derivatives. The encouraging results associated with E5 call for extended research and clinical validation, leading to novel and more effective cancer therapies.

5 August 2023 in Journal of Toxicology
Verified
Journal Article
Open access
PDF file
XLXi Liu
Xi Liu
CCChangmeng Cui
Changmeng Cui
WSWenxue Sun
Wenxue Sun
JMJunjun Meng
Junjun Meng
JGJinxiu Guo
Jinxiu Guo
PJPei Jiang
Pei Jiang
Objective. It is well known that paclitaxel (PTX)-induced neurotoxicity seriously affects the quality of life of patients and is the main reason for reducing the dose of chemotherapy or even stopping chemotherapy. The current data are limited, and further information is required for practice and verification. The aims of this study were to clarify the molecular mechanism underlying PTX-induced neurotoxicity by combining in vivo and in vitro metabolomics studies and provide new targets for the prevention and treatment of PTX-induced neurotoxicity. Methods. In the in vivo study, a PTX-induced neurotoxicity mouse model was established by intraperitoneal injection of PTX (6 mg/kg every three days) for two consecutive weeks. After verification by water maze tests and HE staining of pathological sections, hippocampal metabolites were measured and the differential metabolites and related metabolic pathways were identified by multivariate statistical analysis. In the in vitro study, we investigated the effects of PTX on mouse hippocampal neuron cells, assessing the concentration and time of administration by MTT assays. After modeling, the relevant metabolites in the TCA cycle were quantified by targeted metabolomics using stable isotope labeling. Finally, the key enzymes of the TCA cycle in tissues and cells were verified by RT-PCR. Results. Administration of PTX to model mice resulted in neurological damage, shown by both water-maze tests and hippocampal tissue sections. Twenty-four metabolites and five associated metabolic pathways were found to differ significantly between the hippocampal tissues of the model and control groups. These included metabolites and pathways related to the TCA cycle and pyruvate metabolism. Metabolomics analysis using stable isotope labeling showed significant changes in metabolites associated with the TCA cycle compared with the control group ( ). Finally, RT-PCR verified that the expression of key enzymes in the TCA cycle was changed to different degrees in both hippocampal tissues and cells. Conclusion. Our results showed that PTX neurotoxicity in hippocampal tissue and neuron cells was associated with inhibition of the TCA cycle. This inhibition leads to brain insufficiency and impaired metabolism, resulting in various neurotoxic symptoms.